Drug shortage
Erythromycin Topical Gel · Mylan Pharmaceuticals Inc., a Viatris Company
FDA drug shortage · To Be Discontinued · updated Feb 14, 2025
Key facts
| Generic name | Erythromycin Topical Gel |
|---|---|
| Proprietary name | Erygel |
| Company | Mylan Pharmaceuticals Inc., a Viatris Company |
| Presentation | Erygel, Topical Gel, 20 mg/1 g (NDC 0378-8075-93) |
| Dosage form | Topical Gel |
| Strength | 20 mg/1 g |
| Status | To Be Discontinued |
| Therapeutic category | Anti-Infective Dermatology |
| Package NDCs | 0378-8075-93 |
| First posted | Feb 14, 2025 |
| Last updated | Feb 14, 2025 |
| Discontinued | Feb 14, 2025 |
At a glance
- 1–9 Package NDCs affected
- 1–9 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: